Bildnachweis: ITM. The radiopharmaceutical industry is entering a new era. Driven by clinical breakthroughs, regulatory ...

BWX Technologies reached a record high, leading nuclear-related stocks on reports the US Secretary of Transportation is set ...

(ST. JOSEPH, Mo) Mosaic Life Care is advancing its cancer treatment for patients with metastatic prostate cancer. PLUVICTO is ...

Pluvicto (lutetium-177 vipivotide tetraxetan) is a radioligand therapy that targets the PSMA protein on prostate cancer cells ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical ...

Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 Results Release Conference Call and Live Webcast. [Operator Instructions].

Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

Radiopharmaceuticals have become indispensable tools in precision medicine, revolutionizing diagnostic imaging and targeted therapeutic strategies. This manuscript provides an overview of advancements ...

Asli Munzur looked at blood mutations caused by 2 cancer treatments to work out side effects of Pluvicto, recently approved for treating prostate cancer.